PNC Financial Services Group’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.8K Buy
2,434
+369
+18% +$2.11K ﹤0.01% 4025
2026
Q2
$10.9K Sell
2,065
-5
-0.2% -$22 ﹤0.01% 4010
2026
Q1
$7.76K Hold
2,070
– – ﹤0.01% 4031
2025
Q4
$6.23K Buy
2,070
+31
+2% +$78 ﹤0.01% 4114
2025
Q3
$3.87K Buy
+2,039
New +$3.56K ﹤0.01% 4274
2023
Q3
– Sell
-456
Closed -$4.73K – 4607
2023
Q2
$4.73K Buy
456
+93
+26% +$841 ﹤0.01% 4101
2023
Q1
$2.94K Buy
+363
New +$4.61K ﹤0.01% 4190
2020
Q2
– Sell
-42
Closed – – 3897
2020
Q1
$0 Hold
42
– – ﹤0.01% 3871
2019
Q4
$0 Hold
42
– – ﹤0.01% 3963
2019
Q3
$0 Hold
42
– – ﹤0.01% 3972
2019
Q2
$0 Hold
42
– – ﹤0.01% 3993
2019
Q1
$0 Hold
42
– – ﹤0.01% 4011
2018
Q4
$0 Hold
42
– – ﹤0.01% 4018
2018
Q3
$1K Sell
42
-5,429
-99% -$93K ﹤0.01% 3979
2018
Q2
$110K Buy
5,471
+1,437
+36% +$26.6K ﹤0.01% 2409
2018
Q1
$71K Buy
4,034
+1
+0% +$21 ﹤0.01% 2643
2017
Q4
$99K Buy
4,033
+83
+2% +$2.02K ﹤0.01% 2448
2017
Q3
$102K Sell
3,950
-660
-14% -$17.7K ﹤0.01% 2376
2017
Q2
$125K Buy
4,610
+950
+26% +$25.8K ﹤0.01% 2264
2017
Q1
$109K Buy
3,660
+1,340
+58% +$38.6K ﹤0.01% 2305
2016
Q4
$63K Buy
+2,320
New +$59.2K ﹤0.01% 2598

Other funds holding ACRS

PNC Financial Services Group's ACRS Position: Q3 2026 in Review

PNC Financial Services Group increased its Aclaris Therapeutics (ACRS) stake by 18% in Q3 2026, buying an estimated $2.11K and bringing the position to 2,434 shares worth $12.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4025.

PNC Financial Services Group first reported a position in ACRS in Q4 2016 and has held it in 21 quarters since. The position peaked at $125K in Q2 2017. 167 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • PNC Financial Services Group held 2,434 shares of Aclaris Therapeutics worth $12.8K as of Q3 2026.
  • PNC Financial Services Group bought 369 Aclaris Therapeutics shares in Q3 2026, an estimated $2.11K.
  • Aclaris Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4025 holding.
  • PNC Financial Services Group first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 21 quarters since.
  • PNC Financial Services Group's Aclaris Therapeutics position peaked at $125K in Q2 2017.
  • 167 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.